Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 1
2001 2
2003 2
2005 1
2006 1
2007 2
2008 6
2010 4
2011 3
2012 6
2013 20
2014 26
2015 24
2016 26
2017 26
2018 13
2019 14
2020 16
2021 20
2022 13
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.
The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; hazard ratio, 0.545; 95% CI, 0.362 to 0.820; P = .0036). The median OS in TMC and TMC-I arms was 6.7 months (95% CI, 5.8 to 8.1) and 1 …
The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; h …
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. WHO Solidarity Trial Consortium, et al. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. N Engl J Med. 2021. PMID: 33264556 Free PMC article. Clinical Trial.
Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate r …
Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence inter …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium. WHO Solidarity Trial Consortium. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2. Lancet. 2022. PMID: 35512728 Free PMC article.
Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76-0.99], p=0.03). Of 1730 not on oxygen initially, 2.9% assigned to remdesivir died versus 3.8% assigned to control (RR 0.76 [0.46-1.28], p=0.30). …
Of those not ventilated but on oxygen, 14.6% assigned to remdesivir died versus 16.3% assigned to control (RR 0.87 [0.76-0.99], p=0.0 …
Comparison of anatomic feasibility of three different multibranched off-the-shelf stent-grafts designed for thoracoabdominal aortic aneurysms.
Bertoglio L, Grandi A, Carta N, Cambiaghi T, Bilman V, Melissano G, Chiesa R. Bertoglio L, et al. J Vasc Surg. 2021 Nov;74(5):1472-1482.e4. doi: 10.1016/j.jvs.2021.04.066. Epub 2021 May 20. J Vasc Surg. 2021. PMID: 34023432 Free article.
RESULTS: Degenerative TAAAs in 268 patients were analyzed. The overall feasibility did not differ significantly (TAMBE, 33%; t-Branch, 39%; E-nside, 43%; P = .271). Access, aortic, and visceral vessel feasibility alone excluded 18% to 22%, 35% to 49% and 21% to 26% …
RESULTS: Degenerative TAAAs in 268 patients were analyzed. The overall feasibility did not differ significantly (TAMBE, 33%; t-Branch …
RETRACTED: Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice.
Patil SP, Jain PD, Sancheti JS, Ghumatkar PJ, Tambe R, Sathaye S. Patil SP, et al. Neuropharmacology. 2014 Nov;86:192-202. doi: 10.1016/j.neuropharm.2014.07.012. Epub 2014 Jul 31. Neuropharmacology. 2014. PMID: 25087727 Retracted.
Fig. 6 b), e) ad f) are the same images from Fig 5 a), b), c) from Patil, S.P., Jain, P.D., Ghumatkar, P.J., Tambe, R., Sathaye, S., 2014. ...Fig. 10a), b) and h) are the same images as Fig. 7 B) in the paper Patil, S.P., Jain, P.D., Ghum …
Fig. 6 b), e) ad f) are the same images from Fig 5 a), b), c) from Patil, S.P., Jain, P.D., Ghumatkar, P.J., Tambe …
Anatomic feasibility of the investigational GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE), off-the-shelf multibranched endograft for the treatment of pararenal and thoracoabdominal aortic aneurysms.
Cambiaghi T, Grandi A, Bilman V, Melissano G, Chiesa R, Bertoglio L. Cambiaghi T, et al. J Vasc Surg. 2021 Jan;73(1):22-30. doi: 10.1016/j.jvs.2020.03.056. Epub 2020 Apr 28. J Vasc Surg. 2021. PMID: 32360681 Free article.
In the L-TAA group, 49% of the cases could have been treated with the TAMBE endograft alone; access feasibility was 85%, aortic feasibility 74%, and visceral vessel feasibility 72%. ...CONCLUSIONS: The TAMBE multibranched endograft can theoretically be employed in h …
In the L-TAA group, 49% of the cases could have been treated with the TAMBE endograft alone; access feasibility was 85%, aortic feasi …
Additional Aortic Coverage With an Off The Shelf, Multibranched Endograft Compared With Custom Made Devices For Endovascular Repair of Pararenal Abdominal Aortic Aneurysms.
Spath P, Tsilimparis N, Furlan F, Hamwi T, Prendes CF, Stana J. Spath P, et al. Eur J Vasc Endovasc Surg. 2023 May;65(5):710-718. doi: 10.1016/j.ejvs.2023.01.030. Epub 2023 Jan 24. Eur J Vasc Endovasc Surg. 2023. PMID: 36707021 Free article.
OBJECTIVE: Pararenal abdominal aortic aneurysms (p-AAA) require complex endovascular aortic repair or open surgical repair with suprarenal clamping. ...OTS: 3.8 0.9; p .001). In 94% of patients, at least one of the available multibranched endografts could have been …
OBJECTIVE: Pararenal abdominal aortic aneurysms (p-AAA) require complex endovascular aortic repair or open surgical repair with supra …
Towards a Cognitive Theory of Cyber Deception.
Cranford EA, Gonzalez C, Aggarwal P, Tambe M, Cooney S, Lebiere C. Cranford EA, et al. Cogn Sci. 2021 Jul;45(7):e13013. doi: 10.1111/cogs.13013. Cogn Sci. 2021. PMID: 34213797
223 results